Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have UnderJuly 31, 2018 6:59 AM Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at BMO CapitalJuly 27, 2018 8:21 AM Bristol-Myers Squibb Co. (BMY) PT Raised to $63 at Morgan StanleyJuly 27, 2018 7:37 AM Merck profit beats, but Keytruda sales fail to impressJuly 27, 2018 6:57 AM